Tag: GLP-1 receptor agonist

1. In this systematic review and meta-analysis, use of glucagon-like peptide-1 receptor agonists (GLP-1RAs) was not associated with a significant ...

1. In this cohort study, dulaglutide, semaglutide, and tirzepatide demonstrated similar risks of gastrointestinal adverse events (AEs) in adults with ...

Amryta’s Sodesta gene therapy gains accelerated approval for ALS The Food and Drug Administration has granted accelerated approval to Sodesta, ...

1. The majority of treatment-related adverse events were mild-to-moderate gastrointestinal events with no reported deaths. 2. Amycretin resulted in significant ...

1. Maximum walking distance at 52 weeks was significantly improved with semaglutide. 2. There were fewer treatment-related serious adverse events ...

1. There was no significant difference in functional outcome between both groups at 96 weeks. 2. Exenatide was safe and ...

1. Patients assigned to semaglutide reported reduced major adverse cardiovascular events, regardless of heart failure subtype. 2. Benefits were consistent ...

Click here to read this article in JAMA Internal Medicine.  ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be ...

1. Semaglutide showed significant improvements in KCCQ-CSS score and reduction in body weight compared to placebo. 2. There were fewer ...

1. A reduced risk of nephrolithiasis was linked with patients with type 2 diabetes (T2D) initiating sodium-glucose cotransporter 2 inhibitor ...